Marinus Pharmaceuticals: Q2 Earnings Insights

Shares of Marinus Pharmaceuticals MRNS were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share fell 306.25% over the past year to ($0.65), which beat the estimate of ($0.69).

Revenue of $1,905,000 rose by 0.00% year over year, which missed the estimate of $2,700,000.

Outlook

Marinus Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 10, 2021

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fpro.benzinga.com%2F&eventid=3194348&sessionid=1&key=D7BBD3D17DC6E8447B1781C07F60BE82&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $20.04

Company's 52-week low was at $1.71

Price action over last quarter: down 12.63%

Company Profile

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.